Core Insights - CRISPR Therapeutics experienced a significant stock price increase of over 9% following the release of its quarterly earnings report, contrasting with a 0.3% decline in the S&P 500 index [1] Financial Performance - For Q4 2024, CRISPR reported revenue of just under $36 million, a substantial decrease from over $201 million in Q4 2023 [2] - The company recorded a GAAP loss of $37 million ($0.44 per share) compared to a profit of $98 million in the same quarter the previous year [2] - Despite the decline in both revenue and profit, the results exceeded consensus analyst estimates, which anticipated revenue of only $7.6 million and a net loss of $1.23 per share [3] Future Outlook - Management indicated that 2024 may be a transitional year for CRISPR, but provided updates that fostered optimism among investors [4] - The company anticipates 2025 to be a "milestone-rich year," with plans for a wider rollout of Casgevy, a treatment for sickle cell disease and transfusion-dependent beta-thalassemia, developed in collaboration with Vertex Pharmaceuticals [5] - CRISPR is also continuing to advance its gene-editing technology to develop effective therapies [5]

Group 1 - CRISPR Therapeutics AG reported a quarterly loss of $0.44 per share, significantly better than the Zacks Consensus Estimate of a loss of $1.15, representing an earnings surprise of 61.74% [1] - The company posted revenues of $35.69 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 252.50%, although this is a decline from $201.21 million in the same quarter last year [2] - Over the last four quarters, CRISPR Therapeutics has surpassed consensus EPS estimates three times, indicating a mixed performance trend [2][6] Group 2 - The current consensus EPS estimate for the upcoming quarter is -$1.43 on revenues of $8.09 million, and for the current fiscal year, it is -$5.25 on revenues of $155.74 million [7] - The Medical - Biomedical and Genetics industry, to which CRISPR Therapeutics belongs, is currently ranked in the top 26% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Regulatory Approvals - CASGEVY became the first-ever approved CRISPR-based gene-editing therapy in 2023, approved in multiple regions including the US and EU for treating eligible patients aged 12 and older with SCD or TDT [599]. Financial Performance - Collaboration revenue for the years ended December 31, 2024, 2023, and 2022 was $35.0 million, $370.0 million, and $0.4 million, respectively, primarily from agreements with Vertex [617]. - Total revenue for 2024 was $37.3 million, down from $371.2 million in 2023, reflecting a decline of $333.9 million [640]. - The net loss for 2024 was $366.3 million, compared to a net loss of $153.6 million in 2023, an increase in loss of $212.6 million [640]. - Other income increased to $103.9 million in 2024 from $71.8 million in 2023, an increase of $32.1 million [640]. - Grant revenue for the year ended December 31, 2024, was $2.3 million, an increase from $1.2 million in 2023 [643]. Expenses - Research and development expenses were $320.7 million in 2024, a decrease of $66.7 million from $387.3 million in 2023 [640]. - General and administrative expenses decreased to $73.0 million in 2024 from $76.2 million in 2023, a reduction of $3.2 million [640]. - Total operating expenses for 2024 were $503.9 million, down from $593.7 million in 2023, representing a decrease of $89.9 million [640]. - Collaboration expense, net, was $110.3 million in 2024, down from $130.3 million in 2023, a decrease of $20.0 million [640]. - Research and development expenses decreased to $320.7 million in 2024 from $387.3 million in 2023, a reduction of approximately 17.2% [644]. - General and administrative expenses were $73.0 million in 2024, down from $76.2 million in 2023, reflecting a decrease of $3.2 million [645]. - Collaboration expense, net, decreased to $110.3 million in 2024 from $130.3 million in 2023, a decline of $20.0 million [646]. Cash and Financing - As of December 31, 2024, the company had $1,903.8 million in cash, cash equivalents, and marketable securities, with an accumulated deficit of $1,366.0 million [649]. - Net cash used in operating activities improved to $142.8 million in 2024 from $260.4 million in 2023 [657]. - Net cash provided by financing activities was $331.9 million in 2024, significantly higher than $62.7 million in 2023 [659]. - The company expects its existing cash and marketable securities to fund operations for at least the next 24 months [663]. - Future contractual payments on operating lease obligations due within one year are $29.4 million, and due greater than one year are $265.2 million [665]. - As of December 31, 2024, the company had cash, cash equivalents, and marketable securities totaling $1,903.8 million, primarily invested in U.S. Treasury securities and government agency securities [669]. Research and Development - The company is advancing several CAR T programs, including CTX112 and CTX131, targeting CD19 and CD70, respectively, with enhanced product profiles and broader patient access [602]. - CTX310 and CTX320 are in vivo programs targeting cardiovascular disease, focusing on ANGPTL3 and Lp(a), respectively, with ongoing clinical trials [607][608]. - The company has established a portfolio of therapeutic programs across four core franchises: hemoglobinopathies, CAR T, in vivo approaches, and type 1 diabetes [596]. - The company is developing gene-edited stem cell-derived therapies for type 1 diabetes, including CTX211, which is in an ongoing clinical trial [610]. - The company has recognized $205 million in revenue from upfront and milestone payments related to its collaboration with Vertex for diabetes therapies [613]. - The company expects to continue incurring research and development costs consistent with its size and stage, potentially increasing as development programs progress [622]. - The company anticipates ongoing general and administrative expenses to support continued research and development activities and potential commercialization of product candidates [624]. Market and Economic Factors - The company does not believe it has a material exposure to interest rate risk, as a 1% change in interest rates would result in an immaterial change in the fair value of its investment portfolio [669]. - The company faces exposure to foreign currency exchange rate movements, primarily with the Swiss Franc and British Pound against the U.S. dollar, but foreign currency transaction gains and losses have not been material to its financial statements [670]. - Inflation has generally increased the company's labor, clinical trial, and manufacturing costs, but it has not had a material effect on the company's business or financial results during the years ended December 31, 2024, 2023, and 2022 [671]. Innovation and Partnerships - The CRISPR-X team is focused on innovating next-generation editing modalities to enhance gene editing capabilities [611]. - The company maintains broad partnerships to develop gene editing-based therapeutics across various disease areas, including collaborations with Vertex and others [612]. - Collaboration revenue decreased to $35.0 million in 2024 from $370.0 million in 2023, primarily due to a $200.0 million milestone in 2023 related to the approval of CASGEVY [642].

Financial Performance - CRISPR Therapeutics has approximately $1.9 billion in cash, cash equivalents, and marketable securities as of December 31, 2024, an increase from $1.7 billion at the end of 2023[16] - The net loss for Q4 2024 was $37.3 million, compared to a net income of $89.3 million in Q4 2023[16] - Total revenue for Q4 2024 was $35.691 million, a decrease of 82.3% compared to $201.206 million in Q4 2023[24] - Collaboration revenue for the full year 2024 was $35 million, down from $370 million in 2023, representing a decline of 90.5%[24] - Cash and cash equivalents as of December 31, 2024, were $298.257 million, down from $389.477 million as of December 31, 2023[26] - Total assets increased slightly to $2.242 billion as of December 31, 2024, from $2.230 billion in 2023[26] - Total shareholders' equity rose to $1.932 billion in 2024, compared to $1.883 billion in 2023, an increase of 2.6%[26] Research and Development - R&D expenses for Q4 2024 were $82.2 million, down from $95.1 million in Q4 2023, primarily due to reduced external research and manufacturing costs[16] - Research and development expenses for Q4 2024 were $82.155 million, compared to $95.144 million in Q4 2023, a decrease of 13.6%[24] - Clinical trials for next-generation CAR T product candidates CTX112 and CTX131 are ongoing, with updates expected in mid-2025[1] - CTX310 is in an ongoing Phase 1 clinical trial targeting ANGPTL3, with updates expected in the first half of 2025[10] - CTX320 is also in a Phase 1 clinical trial targeting LPA, with updates anticipated in the first half of 2025[10] - Updates on lead in vivo cardiovascular programs are anticipated in the first half of 2025[2] Product Development and Partnerships - More than 50 authorized treatment centers (ATCs) have been activated globally for CASGEVY, with over 50 patients having undergone cell collection by the end of 2024[3] - CRISPR Therapeutics has formed a strategic partnership with Nkure Therapeutics to co-develop and co-commercialize CTX112 in India[1] - The company has received approval for CASGEVY® (exa-cel) in several countries to treat sickle cell disease and transfusion-dependent beta thalassemia, marking a significant milestone[21] - CRISPR Therapeutics is focusing on expanding its gene editing programs and has formed strategic partnerships with leading companies, including Vertex Pharmaceuticals[21] - The company anticipates potential expansion into new indications and aims to enhance its manufacturing capabilities for ongoing and planned clinical trials[21] Future Outlook - The company expects significant growth in new patient initiations for cell collection throughout 2025[3]

Core Insights - CRISPR Therapeutics is positioned for significant advancements in 2025, with multiple key updates expected across its clinical and commercial portfolio, particularly with the ongoing launch of CASGEVY® and updates on various product candidates [1][2][3] Product Development and Pipeline - The ongoing launch of CASGEVY® is gaining momentum, with over 50 authorized treatment centers activated globally and more than 50 patients having undergone cell collection by the end of 2024; significant growth in new patient collections is anticipated in 2025 [1][3] - Clinical trials for next-generation CAR T product candidates, CTX112™ and CTX131™, are ongoing, targeting CD19 and CD70 across multiple indications, with updates expected in mid-2025 [1][5] - A global strategic partnership has been established with Nkure Therapeutics to co-develop and co-commercialize CTX112 in India, aiming to accelerate its development in regions with unmet medical needs [1][5] - Clinical trials for in vivo gene editing product candidates, CTX310™ and CTX320™, targeting ANGPTL3 and LPA respectively, are ongoing, with updates expected in the first half of 2025 [1][12] Financial Performance - As of December 31, 2024, the company reported a strong balance sheet with approximately $1.9 billion in cash, cash equivalents, and marketable securities, an increase from $1.7 billion at the end of 2023 [1][20] - Research and development expenses for Q4 2024 were $82.2 million, a decrease from $95.1 million in Q4 2023, primarily due to reduced external research and manufacturing costs [10] - The net loss for Q4 2024 was $37.3 million, compared to a net income of $89.3 million in Q4 2023, reflecting changes in revenue and expenses [10][19]

Core Viewpoint - CRISPR Therapeutics is set to report its fourth-quarter and full-year 2024 earnings, with expectations of a sales figure of $10.13 million and a loss of $1.15 per share, while the loss per share estimate for 2025 has increased from $5.17 to $5.21 in the last month [1][11]. Earnings Performance - The company has shown a decent performance over the past four quarters, beating earnings estimates in three out of four quarters, with an average surprise of 100.64% [4][5]. - In the last reported quarter, CRISPR's earnings exceeded expectations by 24.06% [4]. Earnings Estimates - CRISPR Therapeutics has an Earnings ESP of +8.09%, with the most accurate estimate at a loss of $1.06 per share compared to the Zacks Consensus Estimate of a loss of $1.15 [7][6]. Revenue Drivers - The company's revenue is currently bolstered by grants and collaboration revenues from its partnership with Vertex Pharmaceuticals [9]. - The recently approved gene therapy, Casgevy, is expected to contribute $10 million in sales for CRISPR in the fourth quarter, marking the first marketed product in its portfolio [10][11]. Pipeline Development - CRISPR is advancing its pipeline with two next-generation CAR-T therapy candidates, CTX112 and CTX131, currently in phase I/II studies, along with two in-vivo candidates, CTX310 and CTX320, in separate phase I clinical studies [12][13]. Stock Performance and Valuation - Over the past year, CRISPR's stock has declined by 41%, underperforming the industry and broader market indices [15][16]. - The company's shares trade at a price/book ratio of 1.79, which is lower than the industry average of 3.71, indicating attractive valuation [18]. Investment Thesis - With the approval of Casgevy, CRISPR has overcome a significant hurdle regarding revenue generation, although the treatment process may delay revenue recognition [20]. - The partnership with Vertex provides a competitive advantage over rivals, as CRISPR is the first to market an approved CRISPR-based therapy [21]. Future Outlook - The upcoming earnings report is anticipated to be a major catalyst for CRISPR, as it will be the first quarter to record revenues from Casgevy, providing insights into market demand and potential [23].

Readers may recall my last article from October 2024 – a deep dive into CRISPR Therapeutics AG (NASDAQ: CRSP ) – in which I outlined several catalysts for the company and its stock going forward. Giving it a buyI have been investing in the stock market since I was 17 years old, and over the 25+ years since I have learned the joy of compounding, the value of dividend reinvesting, and the principle that patient investing through good times and bad brings the greatest rewards. I believe the key to creating wea ...

CRISPR Therapeutics AG (CRSP) closed at $41.21 in the latest trading session, marking a -1.44% move from the prior day. The stock trailed the S&P 500, which registered a daily loss of 0.47%. Meanwhile, the Dow lost 0.31%, and the Nasdaq, a tech-heavy index, lost 0.51%.The company's stock has climbed by 6.22% in the past month, exceeding the Medical sector's gain of 3.2% and the S&P 500's gain of 1.67%.Investors will be eagerly watching for the performance of CRISPR Therapeutics AG in its upcoming earnings d ...

ZUG, Switzerland and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the Guggenheim SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 2:00 p.m. ET. A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website ...

CRISPR Therapeutics AG (CRSP) closed at $43.42 in the latest trading session, marking a -1.83% move from the prior day. The stock trailed the S&P 500, which registered a daily loss of 0.29%. Meanwhile, the Dow experienced a drop of 0.32%, and the technology-dominated Nasdaq saw a decrease of 0.5%.Heading into today, shares of the company had gained 7.69% over the past month, outpacing the Medical sector's gain of 1.54% and the S&P 500's gain of 2.52% in that time.The investment community will be closely mon ...